Nirmatrelvir/ritonavir use in patients with COVID-19 on hemodialysis: a case series

Patients undergoing hemodialysis (HD) are particularly vulnerable to coronavirus disease 2019 (COVID-19) and are at increased risk of developing severe infection. However, given the exclusion of such patients from clinical trials, there are limited data regarding the effectiveness of the antiviral d...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ai-hua, Diao, Zong-li, Wang, Gang, Guan, Yi-ming, Liu, Ying-jie, Tian, Dong-li, Zhao, Yu-chao, Huang, Hong-dong, Liu, Wen-hu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129908/
https://www.ncbi.nlm.nih.gov/pubmed/37677996
http://dx.doi.org/10.1016/j.diagmicrobio.2023.115969
_version_ 1785030858114072576
author Zhang, Ai-hua
Diao, Zong-li
Wang, Gang
Guan, Yi-ming
Liu, Ying-jie
Tian, Dong-li
Zhao, Yu-chao
Huang, Hong-dong
Liu, Wen-hu
author_facet Zhang, Ai-hua
Diao, Zong-li
Wang, Gang
Guan, Yi-ming
Liu, Ying-jie
Tian, Dong-li
Zhao, Yu-chao
Huang, Hong-dong
Liu, Wen-hu
author_sort Zhang, Ai-hua
collection PubMed
description Patients undergoing hemodialysis (HD) are particularly vulnerable to coronavirus disease 2019 (COVID-19) and are at increased risk of developing severe infection. However, given the exclusion of such patients from clinical trials, there are limited data regarding the effectiveness of the antiviral drug nirmatrelvir/ritonavir (N/R) in patients on HD. We prescribed N/R to four patients on HD with COVID-19 after obtaining informed consent. Their clinical symptoms were improved at approximately 3 days after N/R administration. The viral load was reduced after approximately 10 days. The main adverse effects were nausea and vomiting. Rational dosage adjustment obtained good tolerance but did not influence the efficacy. These results suggest that N/R may be a promising agent for patients on HD with COVID-19.
format Online
Article
Text
id pubmed-10129908
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-101299082023-04-26 Nirmatrelvir/ritonavir use in patients with COVID-19 on hemodialysis: a case series Zhang, Ai-hua Diao, Zong-li Wang, Gang Guan, Yi-ming Liu, Ying-jie Tian, Dong-li Zhao, Yu-chao Huang, Hong-dong Liu, Wen-hu Diagn Microbiol Infect Dis Article Patients undergoing hemodialysis (HD) are particularly vulnerable to coronavirus disease 2019 (COVID-19) and are at increased risk of developing severe infection. However, given the exclusion of such patients from clinical trials, there are limited data regarding the effectiveness of the antiviral drug nirmatrelvir/ritonavir (N/R) in patients on HD. We prescribed N/R to four patients on HD with COVID-19 after obtaining informed consent. Their clinical symptoms were improved at approximately 3 days after N/R administration. The viral load was reduced after approximately 10 days. The main adverse effects were nausea and vomiting. Rational dosage adjustment obtained good tolerance but did not influence the efficacy. These results suggest that N/R may be a promising agent for patients on HD with COVID-19. Published by Elsevier Inc. 2023-04-26 /pmc/articles/PMC10129908/ /pubmed/37677996 http://dx.doi.org/10.1016/j.diagmicrobio.2023.115969 Text en © 2023 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Zhang, Ai-hua
Diao, Zong-li
Wang, Gang
Guan, Yi-ming
Liu, Ying-jie
Tian, Dong-li
Zhao, Yu-chao
Huang, Hong-dong
Liu, Wen-hu
Nirmatrelvir/ritonavir use in patients with COVID-19 on hemodialysis: a case series
title Nirmatrelvir/ritonavir use in patients with COVID-19 on hemodialysis: a case series
title_full Nirmatrelvir/ritonavir use in patients with COVID-19 on hemodialysis: a case series
title_fullStr Nirmatrelvir/ritonavir use in patients with COVID-19 on hemodialysis: a case series
title_full_unstemmed Nirmatrelvir/ritonavir use in patients with COVID-19 on hemodialysis: a case series
title_short Nirmatrelvir/ritonavir use in patients with COVID-19 on hemodialysis: a case series
title_sort nirmatrelvir/ritonavir use in patients with covid-19 on hemodialysis: a case series
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129908/
https://www.ncbi.nlm.nih.gov/pubmed/37677996
http://dx.doi.org/10.1016/j.diagmicrobio.2023.115969
work_keys_str_mv AT zhangaihua nirmatrelvirritonaviruseinpatientswithcovid19onhemodialysisacaseseries
AT diaozongli nirmatrelvirritonaviruseinpatientswithcovid19onhemodialysisacaseseries
AT wanggang nirmatrelvirritonaviruseinpatientswithcovid19onhemodialysisacaseseries
AT guanyiming nirmatrelvirritonaviruseinpatientswithcovid19onhemodialysisacaseseries
AT liuyingjie nirmatrelvirritonaviruseinpatientswithcovid19onhemodialysisacaseseries
AT tiandongli nirmatrelvirritonaviruseinpatientswithcovid19onhemodialysisacaseseries
AT zhaoyuchao nirmatrelvirritonaviruseinpatientswithcovid19onhemodialysisacaseseries
AT huanghongdong nirmatrelvirritonaviruseinpatientswithcovid19onhemodialysisacaseseries
AT liuwenhu nirmatrelvirritonaviruseinpatientswithcovid19onhemodialysisacaseseries

Ejemplares similares